Companies · Biotechnology

Rosetta Genomics Ltd.

REHOVOT · Biotechnology

Diligence memoA one-page analyst read on Rosetta Genomics Ltd. — recommendation, valuation, rhythm, risks.
$8.5M
Total raised · real
4
Rounds
1.2×
Latest step-up
Top 48%
Sector rank · raised
Seed
Latest stage · inferred · Thu Jan 26 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Rosetta Genomics Ltd. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.90× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era.
  • Within the normal band (90% of peer median) for its niche.
Dormant
  • Last raise 14.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Rosetta Genomics Ltd. is one of 4291 Biotechnology companies tracked from REHOVOT. By capital raised it ranks mid-pack (ahead of 53% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2010-12-01 Raised $2.5M (real) Modeled valuation $111M (est)$2.5M$111MSeed2010Seed · 2010-12-01 Raised $2.5M (real) Modeled valuation $111M (est)$2.5M$111MSeed2010Seed · 2011-02-23 Raised $2.7M (real) Modeled valuation $121M (est)$2.7M$121MSeed2011Seed · 2011-02-23 Raised $2.7M (real) Modeled valuation $121M (est)$2.7M$121MSeed2011Seed · 2011-10-19 Raised $1.5M (real) Modeled valuation $67M (est)$1.5M$67MSeed2011Seed · 2012-01-26 Raised $1.8M (real) Modeled valuation $78M (est)$1.8M$78MSeed2012+$2.5M+$2.7M+$2.7M+$1.5M+$1.8MCumulative $14M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.5M · 2010
Seed extension$2.5M · 2010
Seed extension$2.7M · 2011
Seed extension$2.7M · 2011
Seed extension$1.5M · 2011
Seed extension$1.8M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$77.7M
Base estimate est.
$1.3M
Conservative case
$609.7M
Upside case
$8.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $111.0M · 2010-12-012010Seed · modeled $111.0M · 2010-12-01Seed · modeled $121.0M · 2011-02-23Seed · modeled $121.0M · 2011-02-23Seed · modeled $67.4M · 2011-10-19Seed · modeled $77.7M · 2012-01-262012
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
14.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
3 mo
Avg between rounds
$7.4M/yr
Capital velocity
15.6 yr
On record since
2010
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.2× above median
This company$8.5M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.0× above median
This company$1.8M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.2× above median
This company$77.7M
Sector median$64.2M

Raised more than 53% of sector peers (real $). Modeled value above 54% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #84 of 151.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Signum Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Denali Medical II, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Health Elements, LLC · Seed Raised $4.0M · modeled $177.6M (est)Nkt Therapeutics Inc · Seed Raised $4.0M · modeled $177.6M (est)Surface Logix Inc · Seed Raised $4.0M · modeled $177.6M (est)Fe3 Medical, Inc. · Seed Raised $5.4M · modeled $177.1M (est)Proteonomix, Inc. · Seed Raised $3.8M · modeled $169.0M (est)SRS Medical Systems, Inc. · Seed Raised $3.8M · modeled $167.4M (est)Origen Therapeutics Inc /Ca · Seed Raised $3.7M · modeled $166.2M (est)Vivebio, LLC · Seed Raised $3.7M · modeled $163.1M (est)O2 Medtech Inc · Seed Raised $7.1M · modeled $160.3M (est)Biothera, Inc. · Seed Raised $3.5M · modeled $155.4M (est)Rosetta Genomics Ltd. (this company) Raised $8.5M · modeled $77.7M (est)Rosetta Genomics Ltd.
CompanyStageRaised · realValue · estvs peer med.
Signum Biosciences, Inc.Seed$4.0M$177.6M2.05×
Denali Medical II, Inc.Seed$4.0M$177.6M2.05×
Health Elements, LLCSeed$4.0M$177.6M2.05×
Nkt Therapeutics IncSeed$4.0M$177.6M2.05×
Surface Logix IncSeed$4.0M$177.6M2.05×
Fe3 Medical, Inc.Seed$5.4M$177.1M2.05×
Proteonomix, Inc.Seed$3.8M$169.0M1.95×
SRS Medical Systems, Inc.Seed$3.8M$167.4M1.93×
Origen Therapeutics Inc /CaSeed$3.7M$166.2M1.92×
Vivebio, LLCSeed$3.7M$163.1M1.88×
O2 Medtech IncSeed$7.1M$160.3M1.85×
Biothera, Inc.Seed$3.5M$155.4M1.79×
Rosetta Genomics Ltd. this companySeed$8.5M$77.7M0.90×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.5M2010-12-01$12.5M$111.0M90%
Seed$2.5M2010-12-01$12.5M$111.0M90%
Seed$2.7M2011-02-23$13.6M$121.0M90%
Seed$2.7M2011-02-23$13.6M$121.0M90%
Seed$1.5M2011-10-19$7.6M$67.4M90%
Seed$1.8M2012-01-26$8.8M$77.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.5M2010-12-01
    • First recorded raise — entered as Seed.
  2. Seed$2.5M2010-12-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  3. Seed$2.7M2011-02-23
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  4. Seed$2.7M2011-02-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  5. Seed$1.5M2011-10-19
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
  6. Seed$1.8M2012-01-26
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
Intelligence
2012 ~Q2
Modeled next raise · ~3mo cadence
$2.0M
Modeled next size est.range $1.8M$3.2M
1.2×
Last step-up
$7.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Sidransky6 other2012-01
BRIAN MARKISON2 other2012-01
Kenneth Berlin1 other2010-12
Oded Biran1 other2012-01
Tali Yaron-Eldar1 other2012-01
Ayelet Chajut2010-12
Brian A Markison2010-12
David Shoshani Sidransky2010-12
Gerald Dogon2012-01
Gerald Shoshani Dogon2010-12
Isaac Shoshani Bentwich2010-12
Joshua Rosensweig2012-01
Joshua Shoshani Rosensweig2010-12
Keren Givli2010-12
Moshe Shoshani Many2010-12
Racheli Shoshani Vizman2010-12
Ranit Aharonov2010-12
Tali Shoshani Yaron-Eldar2010-12
Tami Fishman Jutkowitz2010-12
Tina Fishman Edmonston2010-12
Tomer Assis2012-01
Tzipora Shoshani Kupitz2010-12
Yoav Shoshani Chelouche2010-12
Registry & provenance

Rosetta Genomics Ltd. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1362959
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Tamir Biotechnology, Inc.BiotechnologySeed$8.4M$35.9Mnetwork1 shared operator · same sector · same stage
Advaxis, Inc.BiotechnologySeries A$53.8M$3.2Mnetwork2 shared operators · same sector
Enumeral Biomedical Corp.BiotechnologySeed$8.4M$89.5Msame sector · same stage
20/20 GeneSystems, Inc.BiotechnologySeed$8.7M$88.8Msame sector · same stage
In Cytu IncBiotechnologySeed$7.9M$82.6Msame sector · same stage
PhysioSonics, IncBiotechnologySeed$7.9M$66.6Msame sector · same stage
Linkage Biosciences, Inc.BiotechnologySeed$7.4M$68.6Msame sector · same stage
Protalex IncBiotechnologySeed$7.3M$63.3Msame sector · same stage
Frequently asked
How much funding has Rosetta Genomics Ltd. raised?
Rosetta Genomics Ltd. has raised approximately $8.5M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Rosetta Genomics Ltd.'s estimated valuation?
Provath's modeled valuation for Rosetta Genomics Ltd. is approximately $77.7M (modeled range $1.3M–$609.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Rosetta Genomics Ltd. at?
Rosetta Genomics Ltd.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Thu Jan 26.
What does Rosetta Genomics Ltd. do and where is it based?
Rosetta Genomics Ltd. operates in the Biotechnology sector, based in REHOVOT.
Explore related

See where Rosetta Genomics Ltd. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Rosetta Genomics Ltd., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.